Translational potential of naloxone and naltrexone as TLR4 antagonists.

PubWeight™: 1.15^‹?› | Rank: Top 10%

🔗 View Article (PMID 25109569)

Published in Trends Pharmacol Sci on August 07, 2014

Authors

Phil Skolnick¹, Hirsch Davis², Derrick Arnelle³, Daniel Deaver³

Author Affiliations

1: Division of Pharmacotherapies and Medical Consequences of Drug Abuse, NIH, 6001 Executive Boulevard, Room 4123, MSC 9551 Bethesda, MD 20892-9551, USA. Electronic address: phil.skolnick@nih.gov.
2: Division of Pharmacotherapies and Medical Consequences of Drug Abuse, NIH, 6001 Executive Boulevard, Room 4123, MSC 9551 Bethesda, MD 20892-9551, USA.
3: Life Sciences and Toxicology Unit, Alkermes, Inc., 852 Winter Street, Waltham, MA 02451, USA.

Articles citing this ↘

International Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and disease. Pharmacol Rev (2015) 0.92

Lack of Specific Involvement of (+)-Naloxone and (+)-Naltrexone on the Reinforcing and Neurochemical Effects of Cocaine and Opioids. Neuropsychopharmacology (2016) 0.84

In vivo veritas: (+)-Naltrexone's actions define translational importance: A letter in response to Skolnick et al. 'Translational potential of naloxone and naltrexone as TLR4 antagonists'. Trends Pharmacol Sci (2014) 0.79

Structure-Activity Relationships of (+)-Naltrexone-Inspired Toll-like Receptor 4 (TLR4) Antagonists. J Med Chem (2015) 0.76

Role of microglia in ischemic focal stroke and recovery: focus on Toll-like receptors. Prog Neuropsychopharmacol Biol Psychiatry (2016) 0.75

Articles cited by this ↗

The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci (2009) 3.06